戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  with short-gut syndrome caused by recurrent desmoid tumor.
2 ents with recurrent, refractory, progressive desmoid tumors.
3 luding colorectal cancer, breast cancer, and desmoid tumors.
4 usion, CTNNB1 mutations are highly common in desmoid tumors.
5 familial adenomatous polyposis (FAP)-related desmoid tumors.
6  and in 29% of HG-FS cases but only in 4% of desmoid tumors.
7  and trisomy 20 are nonrandom aberrations in desmoid tumors.
8  margins is the treatment of choice for most desmoid tumors.
9 ctively followed 206 patients with extremity desmoid tumors.
10 d quality of life in adults with progressing desmoid tumors.
11 n factor CREB3L1 as genetic dependencies for desmoid tumors.
12 l of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Crit
13                                      Purpose Desmoid tumors (aggressive fibromatosis) arise from conn
14                                           In desmoid tumors, aggressive attempts at achieving negativ
15                                              Desmoid tumors also contained a subclass of fibrocytes l
16                               A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (
17 t certain patients with FAP at high risk for desmoid tumors and could be future targets for research.
18 Medline and Embase to identify subjects with desmoid tumors and FAP.
19                                              Desmoid tumors and fibrosarcomas (FS) are part of a wide
20 t mortality in patients with intra-abdominal desmoid tumors and identified additional risk factors ab
21 iate between histologically similar cases of desmoid tumors and LG-FS.
22 ndications for transplantation include large desmoid tumors and other intra-abdominal tumors with rea
23 tality rate of patients with intra-abdominal desmoid tumors and to identify prognostic factors for th
24                                              Desmoid tumors are a group of benign, invasive, solid tu
25           The biology and natural history of desmoid tumors are an enigma.
26                                              Desmoid tumors are associated with a variable and unpred
27                                              Desmoid tumors are locally invasive fibromatous tumors,
28                                              Desmoid tumors are nonmalignant neoplasms of mesenchymal
29                INTRODUCTION: Intra-abdominal desmoid tumors are one of the leading causes of death in
30                                              Desmoid tumors are rare mesenchymal neoplasms characteri
31                                              Desmoid tumors are rare, locally aggressive, highly recu
32                                              Desmoid tumors are soft-tissue neoplasms strictly driven
33 cases can extend beyond the fibrous capsule; desmoid tumors associated with the implants; and breast
34 nown regarding the molecular determinates of desmoid tumor behavior.
35 k has focused on the role of beta-catenin in desmoid tumor biology.
36 not metastasize; however, locally aggressive desmoid tumors can cause severe morbidity and loss of fu
37 weighted imaging (CE-SWI) for characterizing desmoid tumors can enhance the separation between fibrou
38 ly induces cell death on primary FAP-related desmoid tumor cells in culture.
39                   In vitro models of patient desmoid tumor cells revealed a direct effect of Tazemeto
40 plex multidisciplinary management needed for desmoid tumor control may underlie significantly increas
41    Patients with atypical lipomatous tumors, desmoid tumors, dermatofibrosarcoma protuberans, angiosa
42 22 specimens from 19 patients diagnosed with desmoid tumor, desmoplastic fibroma, periosteal desmoid
43                                              Desmoid tumor (DT) is a rare and locally aggressive mono
44 three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynov
45            To test this idea, we examined 16 desmoid tumors from FAP-associated and sporadic cases, f
46 and/or radiation and diagnosis of multifocal desmoid tumors highlight the need to develop effective s
47               There is an increased risk for desmoid tumors in individuals with APC mutations between
48                   The standard management of desmoid tumors is resection, but many recur locally.
49  of mesenchymal tumors, we hypothesized that desmoid tumors may arise in patients with FAP after MSCs
50  Hedgehog and Notch signaling, suggests that desmoid tumors may respond to therapies targeting these
51 nt, and penetrant genetic Xenopus tropicalis desmoid tumor models to identify and characterize drug t
52 the treatment of 10 children for progressive desmoid tumor not amenable to standard surgical or radia
53 moid tumor, desmoplastic fibroma, periosteal desmoid tumor, osteofibrous dysplasia, or fibrous dyspla
54 Patients and Methods Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice
55                    After the transplant, the desmoid tumor recurred in the thoracic wall twice and wa
56 the 10 recipients experienced intraabdominal desmoid tumor recurrence or developed de novo visceral a
57 ly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the m
58                     The term fibromatosis or desmoid tumor refers to a group of benign fibrous growth
59                                 Treatment of desmoid tumors remains a challenge, but new chemotherapy
60 twork, the Desmoid Foundation Italy, and the Desmoid Tumor Research Foundation.
61            Together, our findings argue that desmoid tumors result from the growth of MSCs in a wound
62                                 In contrast, desmoid tumors showed a normal phenotype with these mark
63        Given the variable clinical course of desmoid tumors, the interpretation of factors classicall
64 th the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS.
65 ospective review of 189 consecutive cases of desmoid tumor treated with surgical resection, resection
66                                              Desmoid tumors typically have a stable genome with beta-
67 MSC cell line derived from an FAP-associated desmoid tumor, we confirmed an expected loss in the expr
68  current lack of effective treatment against desmoid tumors, we advocate that endostatin gene therapy
69 ith stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively
70 (two patients) or recurrent (eight patients) desmoid tumor were treated with VBL and MTX for 2 to 35
71 A total of 154 patients with intra-abdominal desmoid tumors were included in the study.
72 rse of a patient with Gardner's syndrome and desmoid tumor who had multiple enterectomies and gradual
73 fit in patients with refractory, progressive desmoid tumors who receive long-term treatment.
74 gut with duodenal adenomatosis and extensive desmoid tumors with pancreaticoduodenal involvement dict
75 otherapy with VBL and MTX appears to control desmoid tumor without significant acute or long-term mor
76 e on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus m